Apotex wins compensation after injunction reversed
A UK court has awarded Canadian generic company Apotex £17.5 million ($28.3 million) in damages after an interim injunction preventing it from making a generic version of French pharmaceutical company Servier's drug Coversyl was overturned.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.